Trans-RosaLEE Study: a Biomarker-directed, Translational Study of High-throughput Molecular Profiling of HR+/HER2- Metastatic Breast Cancer Treated With Endocrine Therapy and Ribociclib.
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Ribociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms Trans-RosaLEE Study; TransRosaLEE
Most Recent Events
- 22 Jun 2023 Status changed from not yet recruiting to recruiting.
- 18 Nov 2022 Planned initiation date changed from 1 Oct 2022 to 1 Jan 2023.
- 12 Sep 2022 New trial record